Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

rward- looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Revenue under

collaborative

agreements $2,194,325 $757,629 $5,209,897 $1,920,192

Product sales 267,901 185,252 492,066 541,420

Total Revenues 2,462,226 942,881 5,701,963 2,461,612

OPERATING EXPENSES:

Cost of product

sales 130,720 59,454 205,036 211,200

Research and

development 10,080,775 6,352,397 27,450,454 13,265,645

Selling, general

and administrative 3,450,450 2,840,683 11,454,228 7,207,544

Total Operating

Expenses 13,661,945 9,252,534 39,109,718 20,684,389

LOSS FROM OPERATIONS (11,199,719) (8,309,653) (33,407,755) (18,222,777)

Interest income 327,561 1,280,871 1,579,210 3,034,985

NET LOSS $(10,872,158) $(7,028,782) $(31,828,545) $(15,187,792)

Basic and diluted

net loss per share $(0.14) $(0.09) $(0.40) $(0.21)

Shares used in

computing net loss

per share,

basic and diluted 80,293,800 76,502,867 79,383,614 73,259,130

<
'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 SPIE Fellow Glenn Boreman, ... Optical Science and Director of the Center for Optoelectronics ... at Charlotte, and co-founder and Chairman of the Board ... the 2015 Vice President of SPIE, the international society ... Stahl announced recent election results at the Annual General ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... SAN FRANCISCO, September 22, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Sept. 22 RF Technologies®, a leading provider of ... announces the hiring of Mark Harwood as company President. ... Inc. and former President and CEO of Arjo, Inc. ... of success in the high-tech, healthcare and medical device ...
... Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, ... National Institutes of Health (NIH) Director,s Opportunity Award for ... Better Treatments" under the American Recovery & Reinvestment Act ...
Cached Biology Technology:Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 2Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 3Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 4Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 5Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 6Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 7Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 8Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 9Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 10RF Technologies® Names Mark Harwood New President 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 3
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... Dartmouth researchers explored the type and number of connections ... assortativity plays on robustness in a study published in ... study found that the assortativity signature contributes to a ... seems that varying the out-out assortativity of TFN models ... of the other three types of assortativity," said Dov ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2
... represent a major and unsolved health issue worldwide. The ... disease, highlighting the urgent need for better knowledge of ... of researchers led by scientists at the Salk Institute ... study kidney diseases, opening new avenues for the future ...
... University of Illinois anthropology professor Ripan Malhi ... first came to the Americas and what happened to them once ... at the meeting, " Ancient DNA: The First Three Decades ," ... Malhi, an affiliate of the Institute for Genomic Biology ...
... cells offer the opportunity to harvest abundant, renewable energy. Although ... spectrum, most solar energy is in the infrared. There is ... are efficient in the infrared but waste much of the ... part of the spectrum. When a photon is absorbed ...
Cached Biology News:Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 2Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 3Ancient, modern DNA tell story of first humans in the Americas 22 for 1 in solar power 2
... Ideal for staining westerns and includes stickers ... Pour spouts in each corner facilitate pouring ... be used for identification. Lid is designed ... for staining several gels simultaneously. Lid also ...
ID clarifier: non-treated with lid...
... Staccato Series of systems provide fast and reliable scalable ... drug development laboratories. Staccato systems are available in three ... Systems Series. ... All Staccato ...
... Staccato Custom Series Systems provide ... drug discovery, genomics, proteomics and drug ... built specifically to customer specifications, providing ... individual needs. Staccato Custom Systems ...
Biology Products: